Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    1
ATC Name B/G Ingredients Dosage Form Price
C10AA07 UBSATOR-CA G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 499,142 L.L
C10AA07 UBSATOR-CA G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 499,142 L.L
A02BC01 ULCAZAL G Omeprazole (sodium) - 40mg 40mg Injectable sterile lyophilised powder for solution 895,895 L.L
A02BC01 ULCAZAL G Omeprazole (sodium) - 40mg 40mg Injectable sterile lyophilised powder for solution 5,916,747 L.L
A03CA02 ULCEDEX G Clidinium bromide - 2.5mg, Chlordiazepoxide - 5mg Tablet 222,694 L.L
R03AL04 ULTIBRO BREEZHALER B Indacaterol - 110mcg, Glycopyronium - 50mcg Capsule, inhalation 4,031,528 L.L
N01AH06 ULTIVA B Remifentanil (HCl) - 5mg 5mg Injectable powder for solution 3,119,058 L.L
N01AH06 ULTIVA B Remifentanil (HCl) - 2mg 2mg Injectable powder for solution 1,703,992 L.L
A07FA02 ULTRA LEVURE B Saccharomyces boulardii - 50mg 50mg Capsule 381,651 L.L
A07FA02 ULTRA LEVURE B Saccharomyces boulardii - 200mg 200mg Capsule 513,348 L.L
A07FA02 ULTRA LEVURE B Saccharomyces boulardii - 100mg 100mg Powder for suspension 536,193 L.L
B05AA01 UMAN ALBUMIN BioHuman Albumin human - 20g/100ml 10g/50ml Injectable solution 3,598,810 L.L
J02AC01 UNAZOL G Fluconazole - 150mg 150mg Capsule 149,742 L.L
A08AB01 UNI-CAL G Orlistat - 120mg 120mg Capsule 1,174,518 L.L
R03DC03 UNICAST G Montelukast (sodium) - 4mg 4mg Tablet, chewable 783,460 L.L
R03DC03 UNICAST G Montelukast (sodium) - 5mg 5mg Tablet, chewable 783,460 L.L
R03DC03 UNICAST G Montelukast (sodium) - 10mg 10mg Tablet, film coated 802,274 L.L
L01XX05 UNIDREA G Hydroxycarbamide (or Hydroxyurea) - 500mg 500mg Capsule, hard 2,539,862 L.L
A10BG03 UNIGLIT G Pioglitazone HCl - 15mg 15mg Tablet 685,360 L.L
C02CA04 UNIPROST G Doxazosin - 4mg 4mg Tablet 452,875 L.L
N06AB05 UNIROX G Paroxetine (HCl) - 20mg 20mg Tablet, film coated 854,684 L.L
J02AC01 UNIZOL MS G Fluconazole - 200mg/100ml 200mg/100ml Injectable solution 1,419,098 L.L
B01AC27 UPTRAVI B Selexipag - 200mcg 200mcg Tablet, film coated 275,097,581 L.L
B01AC27 UPTRAVI B Selexipag - 200mcg 200mcg Tablet, film coated 613,462,617 L.L
B01AC27 UPTRAVI B Selexipag - 400mcg 400mcg Tablet, film coated 275,097,581 L.L
B01AC27 UPTRAVI B Selexipag - 600mcg 600mcg Tablet, film coated 275,097,581 L.L
B01AC27 UPTRAVI B Selexipag - 800mcg 800mcg Tablet, film coated 275,097,581 L.L
B01AC27 UPTRAVI B Selexipag - 1000mcg 1000mcg Tablet, film coated 275,097,581 L.L
B01AC27 UPTRAVI B Selexipag - 1200mcg 1200mcg Tablet, film coated 275,097,581 L.L
B01AC27 UPTRAVI B Selexipag - 1400mcg 1400mcg Tablet, film coated 275,097,581 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2025